AxoGen, Inc.

NasdaqCM AXGN

AxoGen, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

AxoGen, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
  • AxoGen, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
  • AxoGen, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
  • AxoGen, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00, a 0.00% change year over year.
  • AxoGen, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -0.00, a 0.00% change year over year.
Key data
Date Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE)
Market news
Loading...
NasdaqCM: AXGN

AxoGen, Inc.

CEO Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.
IPO Date Dec. 17, 1986
Location United States
Headquarters 13631 Progress Boulevard
Employees 426
Sector Health Care
Industries
Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Similar companies

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

AORT

Artivion, Inc.

USD 29.68

1.16%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

ELMD

Electromed, Inc.

USD 31.05

1.90%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

RXST

RxSight, Inc.

USD 30.08

-2.08%

TMCI

Treace Medical Concepts, Inc.

USD 8.01

-4.19%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

FNA

Paragon 28, Inc.

USD 10.28

-4.28%

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

StockViz Staff

January 15, 2025

Any question? Send us an email